This trial is currently ongoing to investigate the effect of combined capivasertib and fulvestrant on overall survival (OS), but these encouraging findings will likely lead to FDA approval for ER+ advanced breast cancer patients who progressed on endocrine therapy with or without a CDK4/6 inhibitor. This evidence concerns the gene ESR1 and breast carcinoma.